{"id":78174,"date":"2026-09-02T15:17:34","date_gmt":"2026-09-02T07:17:34","guid":{"rendered":"https:\/\/flcube.com\/?p=78174"},"modified":"2026-09-02T15:17:35","modified_gmt":"2026-09-02T07:17:35","slug":"beijing-huasu-wins-nmpa-clinical-trial-approval-for-methylphenidate-er-chewable-tablets-first-domestic-generic-for-adhd-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78174","title":{"rendered":"Beijing Huasu Wins NMPA Clinical Trial Approval for Methylphenidate ER Chewable Tablets, First Domestic Generic for ADHD Treatment"},"content":{"rendered":"\n

Beijing Huasu Pharmaceutical Co., Ltd.<\/strong>, a subsidiary of Beijing Centergate Technologies<\/strong> (SHE: 000931<\/a>), has received clinical trial approval from China’s National Medical Products Administration (NMPA)<\/strong> for its methylphenidate hydrochloride extended-release chewable tablets<\/strong>. The drug will be assessed as a treatment for attention deficit hyperactivity disorder (ADHD<\/strong>) in patients aged 6 years and older.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Agency<\/th>Approval Type<\/th>Product<\/th>Indication<\/th>Date<\/th>Next Steps<\/th><\/tr><\/thead>
NMPA<\/strong> (China)<\/td>Clinical Trial Approval<\/td>Methylphenidate hydrochloride extended-release chewable tablets<\/strong><\/td>ADHD<\/strong> in patients aged 6 years and older<\/td>02 Sep 2026<\/td>Clinical trials to establish safety and efficacy of the generic formulation in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Competitive Landscape<\/h2>\n\n\n\n